PRA Health Sciences (PRAH) provides clinical testing services for the biotech and pharmaceutical industries, mostly in the U.S. and Europe.
The stock boasts a strong IBD Composite Rating of 98 and a best-possible 99 Earnings Per Share Rating, making it the leader of the 30-stock medical research industry.
The group has jumped to No. 79 out of 197, as of Friday, up from No. 166 just three weeks ago.